Compound News and Research

RSS

Oxagen completes £16 Million Series C round funding

Oxagen Limited, a drug discovery and development company specializing in inflammation, announced today the successful completion of a £16 Million ($26.7 Million) Series C round led by Novartis Venture Funds.

24 Nov 2009

Scientists identify factors behind chronic coughing

Scientists have revealed how environmental irritants such as air pollution and cigarette smoke cause people to cough, in research published today in the American Journal of Respiratory and Critical Care Medicine. The

24 Nov 2009

Flaxseed oil may reduce reduce the risk of osteoporosis

Animal studies suggest that adding flaxseed oil to the diet could reduce the risk of osteoporosis in post-menopausal women and women with diabetes, according to a report to be published in the International Journal of Food Safety, Nutrition and Public Health.

23 Nov 2009

Asterand extends its collaboration agreement with Bristol-Myers Squibb

Asterand plc, a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that it has extended its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for access to Asterand's products and services for up to three years.

23 Nov 2009

ASTMH symposium illustrates the need to generate new medicines for infectious diseases

An urgent need for new medicines to treat neglected infectious diseases in the developing world has prompted a growing number of collaborations among academic researchers, non-profit product development partnerships (PDPs), and pharmaceutical and biotechnology companies.

23 Nov 2009

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. By exploiting this mechanism, researchers have been able to powerfully suppress tumor formation in lab testing and in animal models.

22 Nov 2009

Dutch researcher discovers how sulfate groups can be protected during molecule construction

Sulfate groups are crucial building blocks for many molecules but are difficult to handle. Dutch researcher Martijn Huibers has discovered how sulfate groups can be protected during the construction of a molecule. Thanks to his method new molecules, which could be used for the production of medicines, can now be constructed far more easily.

20 Nov 2009

Antimalarial drug resistance endangers malarial control measures

Evidence of resistance to the antimalarial drug artemisinin and its derivatives threatens efforts to control malaria in Southeast Asia, and experts fear artemisinin resistance may spread from the Thailand-Cambodia border to affect other malaria endemic countries. Evidence to such effect was presented today at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

20 Nov 2009

Scientists find how 4-HB is metabolized by the body

It's a naturally occurring brain chemical with an unwieldy name: 4-hydroxybutyrate (4-HB). Taken by mouth, it can be abused or used as a date-rape drug.

20 Nov 2009

ScinoPharm receives Potent Compound Safety Certification from SafeBridge Consultants

ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), announced that its Tainan facility has received the Potent Compound Safety Certification from SafeBridge(R) Consultants, Inc.

20 Nov 2009

Experimental drug to restore function of nerves damaged in spinal cord injuries shows promise

Researchers have shown how an experimental drug might restore the function of nerves damaged in spinal cord injuries by preventing short circuits caused when tiny "potassium channels" in the fibers are exposed.

20 Nov 2009

CDAS, Prestwick Chemical sign drug discovery research agreement

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.

19 Nov 2009

ScinoPharm Taiwan receives the SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that ScinoPharm Taiwan Limited in Tainan, Taiwan has met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and has been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”).

19 Nov 2009

Experts to study how olive oil lowers the level of cytotoxicity in endothelial cells

Experts at Virgen del Rocío Hospital (Seville, Spain) have begun a study on pregnancy preeclampsia on a sample of 30 pregnant women with a view to demonstrating whether or not consumption of olive oil by this population group results in lower levels of cytotoxicity (for example, cholesterol) in endothelial cells (arterial wall cells).

19 Nov 2009

Pfizer and DNDi to battle against HAT, VL and Chagas disease

Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world.

19 Nov 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research.

18 Nov 2009

KAI Pharmaceuticals to receive manufacturing services from Formatech

Today, Formatech announced that they have selected KAI Pharmaceuticals, Inc. and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program.

18 Nov 2009

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.

18 Nov 2009

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

IBM (IBM) scientists have created a one-step point-of-care-diagnostic test, based on an innovative silicon chip, that requires less sample volume, is significantly faster, portable, easy to use, and can test for many diseases, including one of world's leading causes of death, cardiovascular disease.

18 Nov 2009